Thursday, October 15, 2026

Cronos Group Already 7% Up, Almost Five Hours Before The NASDAQ Open

Cronos Group Already 7% Up, Almost Five Hours Before The NASDAQ Open

(VIANEWS) - The NASDAQ opens in less than five hours and Cronos Group's pre-market value is already 7.14% up.

Cronos Group's last close was $1.96, 45.8% under its 52-week high of $3.62.

The last session, NASDAQ ended with Cronos Group (CRON) rising 5.38% to $1.96. NASDAQ rose 0.28% to $12,157.72, following the last session's upward trend on what was a somewhat positive trend trading session.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones brand in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Earnings Per Share

As for profitability, Cronos Group has a trailing twelve months EPS of $-0.46.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -13.63%.

Volume

Today's last reported volume for Cronos Group is 1781735 which is 10.64% below its average volume of 1701790.

Revenue Growth

Year-on-year quarterly revenue growth declined by 11.3%, now sitting on 91.9M for the twelve trailing months.

Sales Growth

Cronos Group's sales growth is negative 5.1% for the present quarter and 7.6% for the next.

More news about Cronos Group (CRON).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com